-
May 18, 2026 13:06 UTC
m_and_a
materiality 1.00
neutral
item 1.02item 2.01item 3.01item 3.03item 5.01item 5.02item 5.03item 9.01
Soleno acquisition by Neurocrine Biosciences completed; all shares bought for $53.00 each
Tender offer expired May 15 with 88.9% of shares tendered; merger closed May 18, 2026.
-
Apr 07, 2026 23:59 UTC
regulatory
materiality 0.75
negative
item 8.01
Soleno withdraws EU marketing application for VIOKAT (PWS hyperphagia)
Voluntarily withdrew MAA for VIOKAT (diazoxide choline) from EMA for Prader-Willi syndrome hyperphagia.
-
Apr 06, 2026 23:59 UTC
m_and_a
materiality 1.00
positive
item 1.01item 7.01item 9.01
Neurocrine to acquire Soleno for $53.00/share in $2.9B all-cash transaction
Deal price $53.00 per share; total equity value ~$2.9B; Soleno board recommends shareholders tender.
-
Mar 16, 2026 23:59 UTC
other
materiality 0.25
neutral
item 5.03item 9.01
Soleno amends bylaws with advance notice changes, forum selection, governance updates
Board approved Amended and Restated Bylaws effective March 16, 2026.
-
Feb 26, 2026 23:59 UTC
leadership
materiality 0.65
neutral
item 5.02item 8.01item 9.01
Soleno Therapeutics appoints Jennifer Fulk as CFO, succeeding retiring James Mackaness
Jennifer Fulk appointed CFO effective March 2, 2026; base salary $525k, target bonus 45%, option for 67,660 shares, RSUs for 39,200 shares.
-
Feb 25, 2026 23:59 UTC
earnings
materiality 0.85
positive
item 2.02item 9.01
Soleno posts Q4 2025 product revenue of $91.7M; full-year net income $20.9M from VYKAT XR launch
FY 2025 net income $20.9M ($0.40 basic EPS) vs. net loss of $175.9M in 2024.
-
Jan 23, 2026 23:59 UTC
other_material
materiality 0.55
neutral
item 5.02item 9.01
Soleno Therapeutics approves FY2026 salary hikes, FY2025 bonuses, equity grants, and new severance plan for NEOs
CEO base salary raised to $765k; CFO to $529k; CCO to $515k; SVP Regulatory to $447k.
-
Jan 12, 2026 23:59 UTC
earnings
materiality 0.85
positive
item 2.02item 9.01
Soleno reports preliminary FY2025 VYKAT XR revenue $189M-$191M; profitable
Preliminary Q4 2025 net revenue $90M-$92M; full-year net revenue $189M-$191M.
-
Nov 12, 2025 23:59 UTC
other_material
materiality 0.75
positive
item 1.01item 2.03item 8.01item 9.01
Soleno initiates $100M accelerated share repurchase; amends loan facility
Entered $100M accelerated share repurchase with Jefferies; initial delivery of ~1,511,553 shares.
-
Nov 04, 2025 23:59 UTC
earnings
materiality 0.85
positive
item 2.02item 9.01
Soleno reports Q3 net income $26M, first profitable quarter; VYKAT XR revenue $66M
Product revenue of $66.0M from VYKAT XR launch (first revenue, vs $0 prior year); net income $26.0M ($0.47 diluted EPS) vs net loss of $76.6M in Q3 2024.
-
Oct 14, 2025 23:59 UTC
leadership
materiality 0.55
positive
item 5.02item 8.01item 9.01
Soleno Therapeutics appoints Mark W. Hahn to Board and Audit Committee
Board increased to 7 seats; Hahn appointed as Class II director, term expiring at 2028 annual meeting.
-
Sep 10, 2025 23:59 UTC
regulatory
materiality 0.65
negative
item 7.01
Soleno reports death of VYKAT XR patient; company says not drug-related
A 17-year-old male with lymphedema, thrombophlebitis, and obesity died from pulmonary embolus; FAERS report filed.
-
Aug 18, 2025 23:59 UTC
other_material
materiality 0.15
neutral
item 7.01item 9.01
Soleno management to present at Guggenheim/Piper Sandler non-deal roadshow Aug 18-19
Senior management will participate in pre-scheduled investor meetings August 18-19, 2025.
-
Aug 06, 2025 23:59 UTC
earnings
materiality 0.80
positive
item 2.02item 9.01
Soleno Q2 2025: $32.7M product revenue from VYKAT XR launch; net loss $4.7M
Product revenue, net $32.7M for Q2 2025, first quarter with VYKAT XR sales (launched April 14).
-
Jul 11, 2025 23:59 UTC
other_material
materiality 0.85
neutral
item 1.01item 8.01item 9.01
Soleno prices $200M public offering of 2.35M shares at $85/share for VYKAT XR commercialization
Priced 2,352,941 shares at $85.00/share; gross proceeds ~$200M before underwriting discounts.
-
Jul 10, 2025 23:59 UTC
earnings
materiality 0.75
positive
item 2.02item 9.01
Soleno expects Q2 2025 VYKAT XR net revenue of $31-33M; cash at $293.8M
Preliminary net revenue of VYKAT XR for Q2 2025: $31.0-$33.0 million.
-
Jun 06, 2025 23:59 UTC
other
materiality 0.05
neutral
item 5.07
Soleno Therapeutics stockholders elect two Class II directors and ratify auditor at 2025 Annual Meeting
Dr. Anish Bhatnagar re-elected with 42,591,113 votes for (92.3% of voted); William Harris re-elected with 32,331,183 votes for (70.0%).